Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348023 · ClinicalTrials.gov registry record · Phase 4
Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension
A Phase 4 study, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00348023 is a Phase 4 study that has completed, run by Innovative Medical.
The verdict
NCT00348023, a Phase 4 study, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.
Interventions
- DRUG Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348023
The ClinicalTrials.gov registry entry for NCT00348023 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Innovative Medical, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5% is the first listed.
NCT00348023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348023 about?
NCT00348023 is a clinical study titled "Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension". Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.
What is the current status of trial NCT00348023?
This trial is currently completed. It is a Phase 4 study.
What interventions are being tested in trial NCT00348023?
The interventions under investigation include: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5% (DRUG).
Who is sponsoring clinical trial NCT00348023?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.